CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Parkinson's Disease
Conditions
Idiopathic Parkinson's Disease
Trial Timeline
Nov 1, 2006 → Nov 1, 2008
NCT ID
NCT00400634About CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) is a phase 2 stage product being developed by Sangamo Therapeutics for Idiopathic Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00400634. Target conditions include Idiopathic Parkinson's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00400634 | Phase 2 | Completed |
Competing Products
20 competing products in Idiopathic Parkinson's Disease